Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Non-Coding RNAs as Biomarkers of Tumor Progression and Metastatic Spread in Epithelial Ovarian Cancer

K. Seborova, R. Vaclavikova, L. Rob, P. Soucek, P. Vodicka

. 2021 ; 13 (8) : . [pub] 20210412

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21017986

Grantová podpora
19-10543S Grantová Agentura České Republiky
NU20-09-00174 Agentura Pro Zdravotnický Výzkum České Republiky
GAUK-1074120 Grantová Agentura, Univerzita Karlova
PROGRES Q28 Grantová Agentura, Univerzita Karlova
No. CZ.02.1.01/0.0/0.0/16_019/0000860 ERDF/ESF

Ovarian cancer is one of the most common causes of death among gynecological malignancies. Molecular changes occurring in the primary tumor lead to metastatic spread into the peritoneum and the formation of distant metastases. Identification of these changes helps to reveal the nature of metastases development and decipher early biomarkers of prognosis and disease progression. Comparing differences in gene expression profiles between primary tumors and metastases, together with disclosing their epigenetic regulation, provides interesting associations with progression and metastasizing. Regulatory elements from the non-coding RNA families such as microRNAs and long non-coding RNAs seem to participate in these processes and represent potential molecular biomarkers of patient prognosis. Progress in therapy individualization and its proper targeting also rely upon a better understanding of interactions among the above-listed factors. This review aims to summarize currently available findings of microRNAs and long non-coding RNAs linked with tumor progression and metastatic process in ovarian cancer. These biomolecules provide promising tools for monitoring the patient's response to treatment, and further they serve as potential therapeutic targets of this deadly disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21017986
003      
CZ-PrNML
005      
20210729104105.0
007      
ta
008      
210726s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers13081839 $2 doi
035    __
$a (PubMed)33921525
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Seborova, Karolina $u Toxicogenomics Unit, National Institute of Public Health, 100 42 Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic
245    10
$a Non-Coding RNAs as Biomarkers of Tumor Progression and Metastatic Spread in Epithelial Ovarian Cancer / $c K. Seborova, R. Vaclavikova, L. Rob, P. Soucek, P. Vodicka
520    9_
$a Ovarian cancer is one of the most common causes of death among gynecological malignancies. Molecular changes occurring in the primary tumor lead to metastatic spread into the peritoneum and the formation of distant metastases. Identification of these changes helps to reveal the nature of metastases development and decipher early biomarkers of prognosis and disease progression. Comparing differences in gene expression profiles between primary tumors and metastases, together with disclosing their epigenetic regulation, provides interesting associations with progression and metastasizing. Regulatory elements from the non-coding RNA families such as microRNAs and long non-coding RNAs seem to participate in these processes and represent potential molecular biomarkers of patient prognosis. Progress in therapy individualization and its proper targeting also rely upon a better understanding of interactions among the above-listed factors. This review aims to summarize currently available findings of microRNAs and long non-coding RNAs linked with tumor progression and metastatic process in ovarian cancer. These biomolecules provide promising tools for monitoring the patient's response to treatment, and further they serve as potential therapeutic targets of this deadly disease.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Vaclavikova, Radka $u Toxicogenomics Unit, National Institute of Public Health, 100 42 Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic
700    1_
$a Rob, Lukas $u Department of Gynecology and Obstetrics, Third Faculty of Medicine and Faculty Hospital Kralovske Vinohrady, Charles University, 100 42 Prague, Czech Republic
700    1_
$a Soucek, Pavel $u Toxicogenomics Unit, National Institute of Public Health, 100 42 Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic
700    1_
$a Vodicka, Pavel $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic $u Institute of Experimental Medicine, CAS, 142 20 Prague, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, 120 00 Prague, Czech Republic
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 8 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33921525 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20210729104104 $b ABA008
999    __
$a ind $b bmc $g 1676489 $s 1138428
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 8 $e 20210412 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a 19-10543S $p Grantová Agentura České Republiky
GRA    __
$a NU20-09-00174 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a GAUK-1074120 $p Grantová Agentura, Univerzita Karlova
GRA    __
$a PROGRES Q28 $p Grantová Agentura, Univerzita Karlova
GRA    __
$a No. CZ.02.1.01/0.0/0.0/16_019/0000860 $p ERDF/ESF
LZP    __
$a Pubmed-20210726

Najít záznam

Citační ukazatele

Možnosti archivace